Ask why a trial is behind schedule and the answers are usually regulatory approval, recruitment or supply.
Look closer at recruitment and it frequently resolves into something else: sites that cannot open because they have nobody to run the study, or open sites screening slowly because the coordinator is covering three protocols.
Where the delay actually comes from
A clinical trial is a distributed operation. Every participating site needs people who can screen against eligibility, take consent properly, follow a protocol exactly, collect and record data accurately, manage the investigational product, report safety events within defined timelines, and survive monitoring and audit.
That is a specific skill set. It is not the same as clinical practice, and clinicians are not automatically good at it.
A study delayed because a site has nobody trained to run it is recorded as a recruitment problem. It is a workforce problem with a recruitment symptom.
The consequence compounds. Delay extends the timeline, extends cost, and in some cases changes whether a study is viable at all.
What the direction covers
The scope: study design and phases, ethics, monitoring, clinical data and GCP.
Five capabilities.
Study design and phases. What each phase is for, what question it answers, and why a protocol is built the way it is. Staff who understand this make better judgements when something unexpected happens on a Friday afternoon.
Good Clinical Practice. The international standard governing trial conduct. It has legal weight and it is a qualification requirement rather than a guideline.
Ethics and consent. Covered below, because it is misunderstood.
Data collection and management. Source documentation, case report forms, queries, and the principle that the data must be traceable to its source.
Safety reporting. Recognising, classifying and reporting adverse events within defined timelines, with obligations that do not flex.
The site burden nobody costs
Worth naming because it is where trial operations quietly break.
Protocols are more complex than they used to be. More assessments, more visits, more eligibility criteria, more data points per participant. Each addition is individually justified and collectively creates a burden that falls on site staff.
Every study has its own systems. A site running several trials handles several different electronic data capture systems, several randomisation platforms, several training portals, each with its own logins and its own quirks.
Training requirements repeat. Each protocol requires its own training, documented, for each person. A site coordinator can spend a substantial share of their time on training records rather than on participants.
Monitoring visits take site time. Preparing for and hosting monitoring is real work and rarely resourced as such.
The workforce implication: capacity planning for a site has to count the overhead, not only the participant visits. Sites that are counted as having capacity frequently do not.
Where this sits in the domain
Clinical research and clinical trials is the fifth of ten directions in Astra Trainer's medicine and healthtech domain, drawing methodology from public health and epidemiology and connecting to pharmacology, precision medicine, and healthcare systems and regulation.
It also pairs across to the biotechnology domain, where drug discovery and pharmaceutical biotechnology covers the development pipeline these trials sit inside. Sponsors and contract research organisations frequently scope both. Lessons are five minutes, which suits site staff who do not have long blocks and are already carrying protocol training. You can see the ten directions here.
Ethics is the job, not the paperwork
Consent is routinely described as though it were a form. Treating it that way is both an ethical failure and a compliance risk, and the distinction is worth teaching properly.
Consent is a process. It begins before any signature, continues throughout participation, and has to be revisited when something changes. A participant can withdraw at any point without giving a reason and without affecting their care.
Capacity is a judgement. Whether someone can understand, retain, weigh and communicate a decision. It varies with condition, medication and time of day, and it is not established by someone being able to write their name.
Understanding has to be checked rather than assumed. Reading a document to someone is not the same as their understanding it. Good practice involves confirming comprehension of the specific things that matter: that this is research, that participation is voluntary, what the alternatives are.
Therapeutic misconception is common. Participants frequently believe a trial is designed to benefit them personally, particularly when they are unwell and options are limited. Recognising and correcting that belief is part of taking consent honestly, and it requires someone who understands the distinction well enough to explain it kindly.
Vulnerability requires more, not less. Children, people lacking capacity, people in acute distress and people with limited alternatives all need additional safeguards.
Staff who have been trained to obtain a signature will obtain signatures. Staff who understand why consent exists will notice when it is not really present, and that difference is the reason this belongs in a training program rather than in an induction pack.
The roles, named
Clinical research coordinators and study nurses. The people who actually run studies at site. The largest population and the biggest shortage.
Clinical research associates. Monitoring sites on behalf of a sponsor. High turnover and constant demand.
Clinical data managers. Data capture, cleaning and lock. Persistently short and rarely planned for.
Clinical trial pharmacists and pharmacy technicians. Investigational product handling, which carries its own requirements.
Regulatory and start-up specialists. Getting studies approved and sites open, which is where a lot of the timeline sits.
Trial managers and project managers.
Pharmacovigilance and safety staff, with statutory reporting obligations.
Biostatisticians and methodologists, connecting to the epidemiology direction.
Who can be trained into it
Nurses. The strongest pool by a distance. Already understand the clinical setting, patient communication, documentation discipline and safety. What they need is the research framework, which is the shorter half. Many nurses do not know these roles exist.
Pharmacy staff. Into trial pharmacy and into wider coordination roles.
Laboratory staff. Sample handling, processing and chain of custody are already familiar.
Data analysts and administrators. Into clinical data management, which is chronically short.
Life sciences graduates. A traditional entry route that works when paired with structured training rather than assumed to work on its own.
Quality professionals from other regulated industries. The audit and documentation mindset transfers directly.
GCP is a requirement, not a topic. Good Clinical Practice training and protocol-specific training are mandatory, documented and auditable, and conducting a trial without them is a regulatory breach. Several roles also require professional registration. Structured learning builds the understanding that makes people effective and prepares them for these routes. It does not constitute GCP certification, protocol training or delegation of study responsibilities, all of which are the responsibility of the investigator and sponsor.
Why turnover is the real cost
Turnover in clinical research roles is high, and the cost is larger than a replacement cost calculation suggests.
A coordinator who leaves takes protocol-specific knowledge, relationships with participants who trust them, familiarity with local processes, and the working understanding of which investigator to ask about what. A replacement needs protocol training, system access, and months to rebuild all of it.
Meanwhile recruitment slows, queries accumulate and monitoring findings increase.
Two implications. Retention is worth more here than in most functions, because the knowledge is specific and slow to rebuild. And organisations that train a pipeline rather than competing for experienced staff are solving a problem the rest of the sector is recycling among itself.
What to take from this
Trial delay is frequently site staffing wearing a recruitment label.
Running a study is a distinct skill set from clinical practice, and clinicians are not automatically good at it.
The site burden is real and uncounted: protocol complexity, multiple systems, repeated training and monitoring time all consume capacity that capacity planning ignores.
Consent is a process involving capacity and understanding, and therapeutic misconception is common enough to need addressing explicitly.
And nurses are the strongest pool available, mostly do not know these roles exist, and need the shorter half of the training.
Why do clinical trials run late?
Frequently because sites cannot open or cannot screen quickly, which is a staffing constraint recorded as a recruitment problem.
Which roles are hardest to fill?
Clinical research coordinators and study nurses at site level, clinical research associates, and clinical data managers. All three are trainable from adjacent backgrounds and rarely recruited deliberately.
Can nurses move into clinical research?
It is the strongest conversion available. Nurses already hold the clinical setting, communication, documentation and safety layers and need the research framework, which is the shorter half.
Is consent just a form?
No. It is an ongoing process requiring judgement about capacity and confirmation of understanding, and therapeutic misconception is common enough that correcting it is part of taking consent honestly.
Does training replace GCP certification?
No. GCP and protocol-specific training are mandatory, documented and auditable, and delegation of study responsibilities rests with the investigator and sponsor.